ArticleMedical science monitor : international medical journal of experimental and clinical research2026
Diagnostic Performance and Imaging Features of Dual-Phase Contrast-Enhanced CT in Peripheral Lung Cancer: A Prospective Study With Pathological Correlation.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Peripheral lung cancer is characterized by an insidious onset and nonspecific early symptoms, resulting in delayed diagnosis and poor prognosis. Dual-phase contrast-enhanced computed tomography (CT) has potential advantages in visualizing tumor morphology and vascular characteristics; its diagnostic performance concerning pathological findings has not been fully elucidated. MATERIAL AND METHODS This prospective study included 120 patients with suspected peripheral lung cancer. All patients underwent dual-phase contrast-enhanced CT scanning; histopathological examination of biopsy or surgically resected specimens served as the reference standard. Patients were divided into 2 groups: lung cancer (n=81) and control (n=39). CT imaging features were compared between groups. The diagnostic performance of dual-phase contrast-enhanced CT was evaluated by calculating sensitivity, specificity, accuracy, positive likelihood ratio (PLR), and negative likelihood ratio (NLR), along with 95% confidence intervals. RESULTS Dual-phase contrast-enhanced CT demonstrated a sensitivity of 82.72%, specificity of 74.36%, accuracy of 80.00%, PLR of 3.23, and NLR of 0.23 for diagnosis of peripheral lung cancer. Histopathological examination confirmed 81 cases of peripheral lung cancer and 39 benign lesions. Peripheral lung cancer lesions-more frequently located in the right lung-were characterized by irregular shape, blurred margins, and spiculated margins. The incidences of vacuoles, contrast enhancement, vascular invasion, and lymph node metastasis were significantly higher in the lung cancer group than in the control group. CONCLUSIONS Dual-phase contrast-enhanced CT clearly demonstrated the malignant morphological and vascular characteristics of peripheral lung cancer, supporting use as a complementary noninvasive imaging modality for differential diagnosis of suspected peripheral lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.